Ocugen Inc - נכסים נקיים למניה בודדת OCGN

Ocugen, Inc. (OCGN) operates by developing treatments for ocular pathologies, which entails high risks due to the lack of stable cash flow, with the indicator standing at -0.05. This price chart illustrates the performance of the company, whose developments are constrained by strict FDA oversight and costly patenting processes. Furthermore, global conflicts and sanctions significantly hinder the international logistics of biomaterials and the execution of joint research.

To protect the portfolio, fundamental screening utilizes the book value per share, calculated as the ratio of total equity minus intangible assets to the number of outstanding securities. In the case of Ocugen, Inc. (OCGN), this indicator reflects the capitalization of the startup's tangible resources, whose value depends on the success of gene therapies rather than market cycles, as confirmed by the share's book value data.